Lexaria Bioscience Corp (LEXX)

Etorro trading 970x250
Lexaria Bioscience Corp (LEXX) Logo

About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Address: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7

Lexaria Bioscience Corp News and around…

Latest news about Lexaria Bioscience Corp (LEXX) common stock and company :

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) as It Looks to Tap into Various Markets
27 May, 2022 FinancialContent
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Growing Commercial Opportunities
27 May, 2022 FinancialContent
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Establishing Foothold in Huge Nicotine Delivery Space
26 May, 2022 FinancialContent
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space
26 May, 2022 Yahoo! Finance

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/WNblw The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million people said

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Waves in the Growing Antiviral Drug Space with its DehydraTECH Technology
25 May, 2022 FinancialContent
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space
25 May, 2022 Yahoo! Finance

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: https://nnw.fm/WNblw Seems like yesterday people were smoking cigarettes everywher

Nicotine Surges as Smoking Sags
24 May, 2022 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience
19 May, 2022 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective
13 May, 2022 FinancialContent
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry
11 May, 2022 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
06 May, 2022 FinancialContent
Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands
05 May, 2022 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform
28 Apr, 2022 FinancialContent
Lexaria Bioscience (NASDAQ: LEXX) Launches Fourth Human Study For Reducing Hypertension
28 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data
27 Apr, 2022 FinancialContent
Lexaria Bioscience (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research
26 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices
25 Apr, 2022 FinancialContent
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
22 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
21 Apr, 2022 FinancialContent
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
21 Apr, 2022 FinancialContent

Lexaria Bioscience Corp(NASDAQ: LEXX) isreceiving its first-ever patentfor DehydraTECH technology in the enhanced ...

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
21 Apr, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.

53 Biggest Movers From Yesterday
21 Apr, 2022 FinancialContent

Gainers ION Geophysical Corporation (NYSE: IO) shares surged 91.2% to settle at $0.6980 on Wednesday. ION Geophysical was awarded ...

Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
20 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

28 Stocks Moving In Wednesday's Mid-Day Session
20 Apr, 2022 FinancialContent

Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
19 Apr, 2022 FinancialContent
LEXX: Hypertension Results Raise Stakes
19 Apr, 2022 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) has provided several updates related to the hypertension and nicotine programs since our last update in February along with the filing of its 2Q:22 Form 10-Q . Results were reported for the HYPER-H21-3 trial and enrollment has started for HYPER-H21-4. In the nicotine realm, the

Lexaria Commences Multi-Week Human Clinical Hypertension Study
19 Apr, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / April 19, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has begun its multi-week human clinical hypertension study.

Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results From Hypertension Study
18 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria
18 Apr, 2022 FinancialContent
51 Biggest Movers From Thursday
18 Apr, 2022 FinancialContent

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently ...

Lexaria Bioscience Corp (LEXX) is a NASDAQ Common Stock listed in , ,

970x250